Jump to Navigation

Facebook Connect

User login

National Lipid Association Releases Results of Survey on Barriers to PCSK9 Inhibitor Prescription Approval Process

The National Lipid Association (NLA) released on Wednesday the results of its survey on the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor prescription approval process.

New York Lipidologist Becomes President of the National Lipid Association

The National Lipid Association (NLA) announced the election of new President James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, on Saturday at the 2017 Scientific Sessions in Philadelphia.

National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session

The National Lipid Association (NLA) assembled a panel of experts to update its guidance for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy made in the NLA Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 in 2015.

NLA Adds Trio of New Features to 2017 Scientific Sessions

With the National Lipid Association’s 2017 Scientific Sessions in Philadelphia from May 18-21 fast approaching, NLA members have an annual meeting packed full of top insights from respected medical leaders to look forward to.

2017 Scientific Sessions Meeting Coverage

The National Lipid Association has featured highlights from selected presentations at the 2017 Scientific Sessions in Philly.  Read our meeting coverage ... read more

2017 Nominating Committee Report Posted

The 2017 NLA Nominating Committee has posted its recommended slate of NLA Board of Directors and Chapter Officers. The recommended slates of candidates will be presented and voted on by the membership at the NLA Annual Business Meeting Saturday, May 20, 2017. Thank you to all that participated... read more

NLA Partners with PlatformQ Health on CME Series Aimed at Reducing CVD Risk

Clinicians treating patients with elevated LDL-C levels are invited to participate in a new complimentary online CME series on CardioCareLive.com. Stay abreast of PCSK9 inhibitors and their role in decreasing risk of cardiovascular disease. High cholesterol — particularly a high level of low-... read more

FOURIER Trial Reveals Significant Reduction in Cardiovascular Risk

WASHINGTON, D.C., March 17, 2017 —  The FOURIER trial lead investigators announced today that the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events by 15%. The detailed results from the FOURIER outcomes trial were presented at the American... read more



by Dr. Radut.